Ellen Feigal, serving as a director at Xencor Inc. (NASDAQ:XNCR), executed a sale of 6,843 shares of the company's common stock on June 18, 2026. The transaction yielded a total value of $89,369, with each share sold at a price point of $13.06. This divestment was processed under a pre-arranged 10b5-1 trading plan, which Feigal initially adopted on June 26, 2025. Following the completion of this transaction, Feigal maintains a direct ownership stake of 12,340 shares in Xencor common stock.
The insider sale takes place against a backdrop of significant recent performance for Xencor, with shares currently trading at $14.01. This current valuation represents a substantial 48% gain over the past year, contributing to a market capitalization of $1.04 billion. Despite this positive price action, analysis from InvestingPro suggests that the stock may be overvalued at current levels. The assessment highlights ongoing revenue headwinds and profitability challenges facing the biotechnology company. Investors seeking deeper insights into XNCR's financial position can utilize InvestingPro tools, which offer additional exclusive tips to aid in informed decision-making.
Market sentiment surrounding Xencor has recently undergone a notable shift, marked by a downgrade from JPMorgan. The financial institution reduced its rating on Xencor from Overweight to Neutral, citing concerns regarding the company's execution capabilities. Brian Cheng, the analyst at JPMorgan, emphasized the necessity for greater clarity on Xencor's clinical strategies, specifically focusing on the role of XmAb819 within various treatment settings. In conjunction with the rating change, JPMorgan adjusted its price target for Xencor to $13, a reduction from the previous target of $18. These adjustments reflect the firm's anticipation that 2026 will be a pivotal year for clinical execution, prompting investors to carefully weigh these developments when evaluating their positions in Xencor.